[Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].

Gao, H J; Shang, X B; Yu, Z T

Gao, H J; Shang, X B; Yu, Z T.

Afiliación

Gao HJ; Department of Thoracic Surgery, the Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Shang XB; Department of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Yu ZT; Department of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.

Zhonghua Wai Ke Za Zhi ; 57(10): 77-82, 2019 Oct 01.

Article en Zh | MEDLINE | ID: mdl-31510736

Asunto(s)

Antineoplásicos Inmunológicos/uso terapéutico; Neoplasias Esofágicas/tratamiento farmacológico; Receptor de Muerte Celular Programada 1/antagonistas & inhibidores; Neoplasias Esofágicas/inmunología; Humanos; Inmunoterapia/métodos; Pronóstico

Palabras clave

Esophageal neoplasms; Immune checkpoints; Immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google